SEPTEMBER 2021LIFE SCIENCES REVIEW6The last few years have seen tremendous consolidation in both the pharmaceutical and contract research industries. The impact among pharma companies has created a heightened demand for productivity. Consequently, contract research organizations (CROs) have struggled to find their footing in a business where the number of customers has shrunk and the demand for speed and cost-effectiveness has risen. Delivering service excellence when customers' names and addresses are changing regularly is a challenge, resulting in disrupted continuity, broken lines of communication, and policies and relationships thrown into disarray.Pharma industry behavior, such as the co-evolution trend, testifies to the demand for new solutions. Large companies such as GlaxoSmithKline have found that spinning off smaller therapeutic-category-based groups may increase productivity. Such groups are organized like biotech companies and focus on a narrow aspect of drug development. In many cases, those groups operate without the infrastructure of a large pharma company, using outside resources such as CROs instead. Big Pharma itself has realized what smaller companies already know: massive scale is not, in and of itself, the secret to accelerated drug development.With such an emphasis on productivity, companies are pressed to perform research tasks more reliably, with greater accuracy, and at a higher speed. In many cases, that means turning to an outside resource. But only the CROs that master the following keys to success will transform those opportunities into meaningful partnerships.Many CROs have the capability to run a specific list of assays. In the previous scenario, it is the CRO's consultative capabilities-the scientific knowledge, the ability to identify the customer's unique needs, and the ability to offer an outside perspective-that are invaluable. In the past, industry emphasis was on speed and expense, and perhaps less on scientific relevance. But, today's pharma companies realize that the ability to hasten a compound through preclinical stages only to have it fail later does not improve productivity. A CRO that develops scientific solutions to improve lead optimization through better screening is vastly more valuable than a group with a prepackaged assay list and a low price.Let us know your thoughts.EDITORIALThe Challenges to CRO SuccessCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com September - 06 - 2021 02, Issue - 07 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald Donovan*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comDean WinchesterVictor Cruz
< Page 5 | Page 7 >